Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
HOME > REGULATORY
REGULATORY
- Social Security Council Members Reiterate Opposition to Reference Pricing for LLPs, or LLP-Gx Uniform Prices
October 6, 2017
- MHLW to Place Priority on “Mutual Understanding” with Industry: Economic Affairs Chief
October 6, 2017
- “Pediatric Treatment”, “Innovation” Excluded from Ethical/Social Factors in Pilot CEA Program: Chuikyo
October 5, 2017
- MHLW Drops 5-Scale CEA Rating, Pitches Slope-Like Price Adjustment Model: Chuikyo
October 5, 2017
- Chuikyo Mulls over Scope of CEA-Based Price Adjustments - Premium Portion or Total NHI Price?
October 5, 2017
- Payers Oppose Price Hikes based on CEA at 1st Joint Meeting: Chuikyo
October 5, 2017
- Chuikyo Members Object to Extension of Prescription Limit for Injectable Ethical Narcotic
October 5, 2017
- MHLW Wants to Introduce Conditional Early Approval System This Month: Minister
October 3, 2017
- MHLW Presents Four Patterns for Review of Clinical Research That Falls Under “Specified Clinical Research” Category
October 2, 2017
- Drug Makers to Be Required to Disclose Donations, Lecture Fees, and Writing Fees Tied to “Specified Clinical Research”
October 2, 2017
- MHLW to Compile Guidelines for Proper Drug Promotion Activities
October 2, 2017
- (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
- MHLW Unveils Planned Framework for Conditional Early Approval Scheme
September 29, 2017
- Keytruda’s Sakigake Designation Revoked after Opdivo Gastric Cancer Nod
September 29, 2017
- MHLW OKs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med, Ibrance and More
September 28, 2017
- As Complaints of Shortages Grow for Japanese Encephalitis Vaccine, MHLW Plans Centralized Collection/Feedback of Supply-Demand Data for Distributers
September 27, 2017
- Trazenta, Amoxicillin and Others under PMDA Risk Review
September 26, 2017
- Interdepartmental Cooperation Needed to Treat Symptoms Following HPV Vaccination: MHLW Panels
September 26, 2017
- MHLW to Urge Drug Makers to Create Systems to Prevent Improper Promotional Activities: Official
September 25, 2017
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters
September 22, 2017
ページ
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…